Study of the Allergizing Properties of Nanocolloid,99mTc–Al2O3 Radiopharmaceutical in Experiment

The aim of the investigation was to assess the allergizing properties of a new nanocolloidal preparation based on aluminum gamma-oxide labeled by technetium-99m for scintigraphic and intraoperative detection of sentinel lymphatic nodes in experiment.

Materials and Methods. A series of experiments was performed on 80 guinea pigs, 30 Balb/c mice, 40 CBA/CaLac mice and 70 outbred mice of both genders. To study allergenicity various doses of preparation were administered subcutaneously, intramuscularly, intravenously, intradermally as a single injection or by a course. Allergizing properties of the radiopharmaceutical were investigated according to the “Guidelines on the assessment of allergizing properties of drugs”.

Results. Administration of Nanocolloid,99mTc‒Al₂O₃ radiopharmaceutical did not result in the intensification of anaphylaxis systemic reaction in the animals of the examined groups relative to the control. A single injection did not cause inflammatory reaction to Concanavalin A in the examined animals. When guinea pigs were immunized by the preparation, no delayed allergic reaction was revealed. Studying sensitizing effect of the preparation by 20 skin applications no redness or edema of the skin at the site of application was observed.

Conclusion. Nanocolloid,99mTc‒Al₂O₃ radiopharmaceutical in the studied doses and under the selected experimental conditions does not possess allergizing properties.

1. Chernov V.I., Sinilkin I.G., Shiryaev S.V. Radionuklidnoe vyyavlenie storozhevykh limfaticheskikh uzlov. V kn.: Natsional’noe rukovodstvo po radionuklidnoy diagnostike [Radionuclide detection of sentinel lymphatic nodes. In: National guideline on radionuclide diagnosis]. Pod red. Lishmanova Yu.B., Chernova V.I. [Lishmanov Yu.B., Chernov V.I. (editors)]. Tomsk: STT; 2010; p. 336–343.
2. Paredes P., Vidal-Sicart S., Zanуn G., Pahisa J., Fernández P.L., Velasco M., Santamaría G., Ortín J., Duch J., Pons F. Clinical relevance of sentinel lymph node in the internal mammary chain in breast cancer patients. Eur J Nucl Med Mol Imaging 2005; 32(11): 1283–1287, http://dx.doi.org/10.1007/s00259-005-1867-z.
3. Kanayev S.V., Novikov S.N., Zhukova L.A., Zotova O.V., Semiglazov V.F., Krivorotko P.V. Lymphoscintigraphy of individual lymph flow for radiotherapy planning in breast cancer. Voprosy onkologii 2011; 57(5): 616–621.
4. Chernov V.I., Afanasyev S.G., Sinilkin I.G., Titskaya A.A., Avgustinovich A.V. Radionuclide diagnosis for detection of sentinel lymph nodes. Sibirskiy onkologicheskiy zhurnal 2008; 4: 5–10.
5. Schauer A.J., Becker W., Reiser M., Possinger K. The sentinel lymph node concept. Springer Verlag, Heidelberg Berlin New York; 2005, http://dx.doi.org/10.1007/b137529.
6. Afanasyev S.G., Avgustinovich A.V., Chernov V.I., Sinilkin I.G. Radio-guided sentinel lymph node detection in gastric cancer patients. Sibirskiy onkologicheskiy zhurnal 2009; 34(4): 27–32.
7. Maza S., Valencia R., Geworski L., Zander A., Guski H., Winzer K.J., Munz D.L. Peritumoural versus subareolar administration of technetium-99m nanocolloid for sentinel lymph node detection in breast cancer: preliminary results of a prospective intra-individual comparative study. Eur J Nucl Med Mol Imaging 2003; 30(11): 651–688, http://dx.doi.org/10.1007/s00259-003-1128-y.
8. Jurisson S.S., Lydon J.D. Potential technetium small molecule radiopharmaceuticals. Chem Rev 1999; 99(9): 2205–2218, http://dx.doi.org/10.1021/cr980435t.
9. Baishya R., Nayak D.K., Karmakar S., Chattopadhyay S., Sachdeva S.S., Sarkar B.R., Ganguly S., Debnath M.C. Synthesis and evaluation of technetium-99m-labeled bioreductive pharmacophores conjugated with amino acids and peptides for tumor imaging. Chem Biol Drug Des 2015; 85(4): 504–517, http://dx.doi.org/10.1111/cbdd.12437.
10. Geskovski N., Kuzmanovska S., Simonoska Crcarevska M., Calis S., Dimchevska S., Petrusevska M., Zdravkovski P., Goracinova K. Comparative biodistribution studies of technetium-99 m radiolabeled amphiphilic nanoparticles using three different reducing agents during the labeling procedure. J Labelled Comp Radiopharm 2013; 56(14): 689–695, http://dx.doi.org/10.1002/jlcr.3097.
11. Rukovodstvo po provedeniyu doklinicheskikh issledovaniy lekarstvennykh sredstv. Chast’ I [Guideline for preclinical studies drugs. Part I]. Moscow: Grif i K; 2012; 944 p.

Varlamova N.V., Stasyuk E.S., Titskaya A.A., Sinilkin I.G., Larionova L.A., Sherstoboyev E.Y., Trofimova E.S., Ligacheva A.A., Skuridin V.S. Study of the Allergizing Properties of Nanocolloid,99mTc–Al2O3 Radiopharmaceutical in Experiment . Sovremennye tehnologii v medicine 2015; 7(4): 72, https://doi.org/10.17691/stm2015.7.4.09